Current Status of Imaging for Adrenal Malignant Involvement

  • Michael A. Blake
  • Mannudeep K. Kalra
Part of the Cancer Treatment and Research book series (CTAR, volume 143)

Adrenal masses are relatively common in the general population, with a mean prevalence determined from several large autopsy studies of 2.3 percent [1]. Given the propensity for and the clinical importance of adrenal metastatic involvement, accurate diagnosis of adrenal masses is of particular important in oncologic patients. Fortunately non-invasive radiology can usually determine whether a mass is benign or likely malignant (indeterminate lesion), based on recent research into the imaging characteristics of adrenal masses.


Hounsfield Unit Adrenal Mass Washout Rate Adrenocortical Carcinoma Adrenal Adenoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149:273–85.PubMedCrossRefGoogle Scholar
  2. 2.
    Blake MA, Kalra MK, Sweeney AT, et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006:578–585.Google Scholar
  3. 3.
    Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234:479–85.PubMedCrossRefGoogle Scholar
  4. 4.
    Caoili EM, Korobkin M, Francis IR, et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222:629–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Lee M, Hahn P, Papanicolaou N, et al. Benign and malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. Radiology 1991; 179:415–8.PubMedGoogle Scholar
  6. 6.
    Korobkin M, Brodeur FJ, Yutzy GG, et al. Differentiation of adrenal adenomas from nonadenomas using CT attenuation values. AJR Am J Roentgenol 1996; 166:531–6.PubMedGoogle Scholar
  7. 7.
    Singer A, Obuchowski N, Einstein D, Paushter D. Metastasis or adenoma? Computed tomographic evaluation of the adrenal mass. Cleve Clin J Med 1994; 61:200–5.PubMedGoogle Scholar
  8. 8.
    van Erkel A, van Gils A, Lequin M, Kruitwagen C, Bloem J, Falke T. CT and MR distinction of adenomas and nonadenomas of the adrenal gland. J Comput Assist Tomogr 1994; 18:432–8.PubMedGoogle Scholar
  9. 9.
    Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 1998; 171:201–4.PubMedGoogle Scholar
  10. 10.
    Choyke P. ACR Appropriateness Criteria on Incidentally Discovered Adrenal Masses. J Am Coll Radiol 2006; 3:498–504.PubMedCrossRefGoogle Scholar
  11. 11.
    Korobkin MF, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Goodsitt M. Delayed enhanced CT for differentiation of benign from malignant adrenal masses. Radiology 1996; 200:737–42.PubMedGoogle Scholar
  12. 12.
    Korobkin MF, Brodeur FJ, Francis IR, Quint LE, Dunnick NR, Londy F. CT time-attenuation washout curves of adrenal adenomas and nonadenomas. AJR Am J Roentgenol 1998; 170: 747–52.PubMedGoogle Scholar
  13. 13.
    Blake MA, Krishnamoorthy SK, Boland GW, et al. Low-density pheochromocytoma on CT: a mimicker of adrenal adenoma. AJR Am J Roentgenol 2003; 181:1663–8.PubMedGoogle Scholar
  14. 14.
    Jain RK, Munn LL, Fukumura D. Dissecting tumor pathophysiology using intravital microscopy. Nat Rev Cancer 2002; 2:266–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Boland GW, Hahn PF, Pena C, Mueller PR. Adrenal masses: characterization with delayed contrast-enhanced CT. Radiology 1997; 202:693–6.PubMedGoogle Scholar
  16. 16.
    Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol 2000; 175:1411–5.PubMedGoogle Scholar
  17. 17.
    Pena CS, Boland GW, Hahn PF, Lee MJ, Mueller PR. Characterization of indeterminate (lipid-poor) adrenal masses: use of washout characteristics at contrast-enhanced CT. Radiology 2000; 217:798–802.PubMedGoogle Scholar
  18. 18.
    Young WF. The incidentally discovered adrenal mass. N Eng J Med 2007; 356:601–10.CrossRefGoogle Scholar
  19. 19.
    Bae KT, Fuangtharnthip P, Prasad SR, Joe BN, Heiken JP. Adrenal masses: CT characterization with histogram analysis method. Radiology 2003; 228:735–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Remer EM, Motta-Ramirez GA, Shepardson LB, Hamrahian AH, Herts BR. CT histogram analysis in pathologically proven adrenal masses. AJR Am J Roentgenol 2006; 187:191–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Blake MA, Kalra MK, Maher MM, et al. Pheochromocytoma: an imaging chameleon. Radiographics 2004; 24:S87–99.PubMedCrossRefGoogle Scholar
  22. 22.
    Israel GM, Korobkin M, Wang C, Hecht EN, Krinsky GA. Comparison of unenhanced CT and chemical shift MRI in evaluating lipid-rich adrenal adenomas. AJR Am J Roentgenol 2004; 183:215–9.PubMedGoogle Scholar
  23. 23.
    Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics 2001; 21:995–1012.PubMedGoogle Scholar
  24. 24.
    Haider MA, Ghai S, Jhaveri K, Lockwood G. Chemical shift MR imaging of hyperattenuating (>10 HU) adrenal masses: does it still have a role? Radiology 2004; 231:711–716.PubMedCrossRefGoogle Scholar
  25. 25.
    Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 194:131–4.PubMedGoogle Scholar
  26. 26.
    Blake MA, Slattery JM, Kalra MK, et al. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy–initial experience. Radiology 2006; 238:970–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Kumar R, Xiu Y, Yu JQ, et al. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45:2058–62.PubMedGoogle Scholar
  28. 28.
    Metser U, Miller E, Lerman H, Lievshitz G, Avital S, Even-Sapir E. 18F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl Med 2006; 47:32–37.PubMedGoogle Scholar
  29. 29.
    Erasmus JJ, Patz EF, Jr., McAdams HP, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357–60.PubMedGoogle Scholar
  30. 30.
    Minn H, Salonen A, Friberg J, et al. Imaging of adrenal incidentalomas with PET using (11) C-metomidate and (18) F-FDG. J Nucl Med 2004; 45:972–9.PubMedGoogle Scholar
  31. 31.
    Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and. Endocr Rev 2004; 25:309–40.PubMedCrossRefGoogle Scholar
  32. 32.
    Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138:424–9.PubMedGoogle Scholar
  33. 33.
    Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667–80.PubMedCrossRefGoogle Scholar
  34. 34.
    Stone J. Incidentalomas–clinical correlation and translational science required. N Engl J Med 2006; 354:2748–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Blake MA, Sweeney AT, Kalra MK, Maher M. Collision Adrenal Tumors on PET/CT. Am J Roentgenol. 183(3):864–5, 2004.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Michael A. Blake
    • 1
  • Mannudeep K. Kalra
    • 1
  1. 1.Department of RadiologyMassachusetts General HospitalBostonUSA

Personalised recommendations